Specialized pro-resolving mediator network: an update on production and actions.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing preclinical mechanisms and selected human data without systematic review methodology.
PubMed 32885825 · doi:10.1042/EBC20200018
What was done
This narrative review summarizes findings from preclinical animal models and human studies over a 2–3 year period (up to August 2020) regarding specialized pro-resolving mediators (SPMs), including lipoxins, resolvins, protectins, maresins, cysteinyl-SPMs, and n-3 DPA-derived mediators, focusing on their biosynthetic pathways, structural-functional characterization, and receptor targets.
What was found
The abstract reports no quantitative experimental effect sizes or pooled patient data. It notes that PubMed indexed >1,170 publications on resolvins as of August 17, 2020. The authors summarize qualitative evidence showing that SPMs and their downstream receptors stimulate resolution of acute inflammation, facilitate microbial clearance, reduce pain, and promote tissue regeneration.
Why it matters
Highlights the paradigm shift from passive dissipation of inflammation to active resolution mediated by specialized lipid pathways, outlining potential avenues for resolution-targeted therapeutics and precision nutrition in chronic inflammatory diseases.
Limits
As a narrative review, it lacks systematic search criteria, formal study quality assessment, and quantitative synthesis. Much of the underlying mechanistic evidence stems from preclinical laboratory models, and clinical efficacy in specific human disease states remains to be established in rigorous trials.
Cited by
- supports Specialized pro-resolving mediators (SPMs) such as maresins, protectins, and resolvins are metabolites of EPA and DHA that actively resolve inflammation.